Agilent Technologies and Lipomics collaborate to develop research, diagnostic biomarker assays


Agilent Technologies Inc. and Lipomics Technologies Inc. announced that they will collaborate to develop research and diagnostic assays combining Agilent analytical platforms with Lipomics' expertise in biomarker discovery and validation.

The assays will focus on metabolic diseases, a family of related disorders driven in large part by subtle, long-term dysregulation of lipid metabolism. According to the company, Lipomics Technologies provides quantitative, diagnostically accurate measurements of more than 1,500 metabolites, allowing comprehensive profiling of whole-body lipid metabolism. The company's quantitative methods and expertise in lipid biology drive development of clinically relevant diagnostic and research assays.

Other news from the department business & finance

Most read news

More news from our other portals